Efficacy of transurethral botulinum toxin A injections for bladder outlet obstruction: A systematic review and meta-analysis.

Urologia 2024 Vol.91(3) p. 468-476

Gavi F, Ragonese M, Fettucciari D, Bientinesi R, Gandi C, Campetella M, Marino F, Racioppi M, Sacco E, Foschi N

관련 도메인

Abstract

[INTRODUCTION] Botulinum toxin A (BoNT-A) injections in the prostate gland have been used as a minimally invasive option for treating bladder outlet obstruction (BOO). However, the efficacy of transurethral BoNT-A injections for BOO is not well established in the literature. The aim of this study is to collect evidence on the efficacy of transurethral BoNT-A injections for the treatment of BOO.

[MATERIALS AND METHODS] This systematic review and meta-analyses was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. A systematic literature search was performed till December 2022. The study population consisted of adult patients diagnosed with BOO, who underwent transurethral injections of BoNT-A for the treatment of BOO.

[EVIDENCE SYNTHESIS] Out of 883 records, we identified seven studies enrolling 232 participants, of which only one nonrandomized controlled trial was found. Four prospective studies and two retrospective studies. Three studies included patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) and were included in the meta-analysis. Three studies included patients with urethral sphincter hyperactivity. One study included patients with primary bladder neck disease (PBND). All studies showed significant improvements from baseline in maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), and postvoid residual (PVR) at 3 and 6 months. The adverse events were mild in all studies. Hematuria, UTI, and urinary retention were reported across all studies.

[CONCLUSION] In conclusion, transurethral BoNT-A injections have been shown to improve LUTS, QoL, and urodynamic parameters of individuals with BOO at 3 and 6 months after injections, and no serious adverse effects have been reported. However, data on the long-term benefits of this treatment are scarce, and more prospective, randomized studies with larger samples examining various injection techniques, dosages, and extended follow-up of recurrent injections are needed.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 2
해부 transurethral scispacy 1
해부 urinary tract scispacy 1
합병증 urethral sphincter scispacy 1
약물 BOO → bladder outlet obstruction C0005694
Bladder neck obstruction
scispacy 1
약물 transurethral botulinum toxin A scispacy 1
약물 [INTRODUCTION] Botulinum toxin A scispacy 1
약물 transurethral BoNT-A scispacy 1
약물 LUTS → lower urinary tract symptoms scispacy 1
약물 urinary scispacy 1
질환 bladder outlet obstruction C0005694
Bladder neck obstruction
scispacy 1
질환 BOO → bladder outlet obstruction C0005694
Bladder neck obstruction
scispacy 1
질환 lower urinary tract symptoms C0574785
Lower Urinary Tract Symptoms
scispacy 1
질환 prostatic hyperplasia C1704272
Benign Prostatic Hyperplasia
scispacy 1
질환 urethral sphincter hyperactivity scispacy 1
질환 primary bladder neck disease scispacy 1
질환 Prostate C0033572
Prostate
scispacy 1
질환 Hematuria C0018965
Hematuria
scispacy 1
질환 urinary retention C0080274
Urinary Retention
scispacy 1
질환 bladder outlet scispacy 1
질환 benign prostatic hyperplasia scispacy 1
질환 BPH → benign prostatic hyperplasia scispacy 1
질환 bladder neck disease scispacy 1
질환 Prostate Symptom scispacy 1
기타 BoNT-A → Botulinum toxin A scispacy 1
기타 prostate gland scispacy 1
기타 BOO → bladder outlet obstruction scispacy 1
기타 UTI scispacy 1
기타 LUTS → lower urinary tract symptoms scispacy 1

MeSH Terms

Humans; Botulinum Toxins, Type A; Urinary Bladder Neck Obstruction; Treatment Outcome; Urethra; Neuromuscular Agents; Injections

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문